On average, 66.6% ± 34.2%, 69.8% ± 33.4% and 0% of tumor-infiltrating CD8 TRM cells coexpressed CD39, PD-L1, and PD-1, respectively. This evidence concerns the gene ENTPD1 and neoplasm.